Methicillin-resistant Staphylococcus aureus is increasingly responsible for staphylococcal outbreaks in prison. There is limited information on the source of the outbreak strains, risk factors for infection, and transmission of these strains within a prison. We conducted a survey to determine the prevalence of nasal colonization with S. aureus in 2 New York State prisons. S. aureus isolates from clinical cultures collected from all New York State prisons during a 6-month period were compared with the colonizing strains. Analyses were conducted to determine whether prison-level characteristics were associated with colonization or infection with S. aureus. The colonization rate was 25.5% (124/487); 10.5% of the isolates were methicillin resistant, all were staphylococcal chromosomal cassette (SCC)mec type IV, and 61.5% were Panton Valentine leukocidin (PVL) positive. Surprisingly, 21.6% of the methicillin-susceptible isolates were also PVL positive. Of the clinical isolates, 48.3% were methicillin resistant, with 93.1% of the latter being SCCmec type IV and 48.3% being PVL positive. The predominant clone was USA 300. Prison-level risk factors for infection included the proportion of inmates with drug offenses, the length of inmate stay, and the jail from which inmates originated. This study suggests that both new and long-term inmates act as sources of S. aureus strains, with the more virulent of the latter preferentially being selected as pathogens.

No abstract

BackgroundReal-world data on usage and associated outcomes with hereditary angioedema (HAE)-specific medications introduced to the United States (US) market since 2009 are very limited. The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU). This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.ResultsOf 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant. There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes. Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED). Eighteen patients (5.4%) had a central venous access device (CVAD); of these, 5 (27.7%) required hospitalization and 14 (77.7%) had an ED visit. The adjusted relative risk of hospitalization and/or ED visits for patients with a CVAD was 2.6 (95% CI: 0.17, 39.23) compared to C1-INH(IV) users without a CVAD.ConclusionsDespite widespread availability of modern HAE medications in the US, we identified a subset of patients requiring long-term prophylaxis who continue to be burdened by frequent rescue medication usage and/or complications related to the use of CVADs for intravenous HAE medication.

We sought to determine whether sperm donor selection could be improved by using the hyaluronan binding assay (HBA) score to predict live birth rates (LBRs) in donor insemination treatments. Thirty donor samples were included: five fresh samples to assess whether HBA score is affected by cryopreservation and 25 frozen samples from donors whose sperm gave rise to known live births, divided into three groups, with success rates ≥50%, <50-33% and <33%, to examine whether HBA score correlates with LBRs. Correlations with semen analysis parameters, as well as donor demographic factors, known causes of patient subfertility and/or the type of treatment provided were also assessed. There was no significant difference in the mean HBA score pre- and post-cryopreservation (p = 0.998) nor in the HBA score of the three different outcome groups (p = 0.89). HBA score was not significantly affected by other semen analysis parameters (r=0.394, p = 0.127) or any of the other examined factors. This was the first study to investigate HBA score for cryopreserved donor samples with known LBRs. HBA score was not correlated with LBRs in this small pilot study. Larger studies are required to validate HBA score as a tool for sperm donor selection and predictor of LBRs.

tion prescribed between July 2013 and June 2014. Results: Of 2,558 CHC treated patients, 142 patients (5.6%) were identified as having CKD. The mean age of CHC patients with CKD was 61 years compared to 57 years among those without CKD (p< .0001). Compared to CHC patients without CKD (n = 2,416), patients with CKD had significantly more comorbidities including diabetes (53% vs 23%, p< .0001), major depression (15% vs.6%, p= .0007), hypertension (85% vs. 51%, p< .0001) and heart failure (19% vs. 2%, p< .0001). CHC patients with CKD also had higher prevalence of kidney transplants (11% vs.1%, p< .0001) and more liver transplants (35% vs. 6%, p< .0001). For concomitant drug use, CHC patients with CKD had significantly more concomitant drugs (by drug class) during the 2-year baseline period compared to those without CKD (17 vs 11, p< .0001).